



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

PCT/EP200 4 / 0 5 1 7 5 5

REC'D 13 OCT 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03447210.0

**PRIORITY
DOCUMENT**

**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)**

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Anmeldung Nr:
Application no.: 03447210.0
Demande no:

Anmeldetag:
Date of filing: 14.08.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DSB Invest Holding SA.
1 rue Goethe
1637 Luxembourg
LUXEMBOURG

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Use of melatonin for improving the healing response after vascular injury by
inhibition of inflammation induced by the injury and the prevention of cell
proliferation and cell ingrowth into an endoluminal implant

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K31/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

"Use of Melatonin for improving the healing response after vascular injury by inhibition of inflammation induced by the injury and the prevention of cell proliferation and cell ingrowth into an endoluminal implant

5

Field of the Invention

Delivery of a therapeutic agent locally, particularly from an intraluminal prosthesis such as a coronary stent, directly from the surface of the prosthesis or from pores, micropores, or perforations in the prosthesis body, directly bounded on the prosthesis or mixed or bound to a polymer coating applied on the prosthesis, or mixed or bound to a glue applied to the prosthesis, to modulate the healing response after vascular injury, to improve endothelial cell regrowth, and to inhibit inflammation induced by the injury caused by the implantation of the intraluminal prosthesis and inhibiting tissue proliferation and thereby preventing stenosis of the prosthesis.

15

Background of the Invention:

Re-narrowing (restenosis) of an atherosclerotic coronary artery after percutaneous transluminal coronary angioplasty (PTCA) occurs in 10-50% of patients undergoing this procedure and subsequently requires either further angioplasty or coronary artery bypass graft. While the exact hormonal and cellular processes promoting restenosis are still being determined, our present understanding is that the process of PTCA, besides opening the atherosclerotically obstructed artery, also injures resident coronary arterial smooth muscle cells (SMC).

25

In response to this injury, adhering platelets, infiltrating macrophages, leukocytes, or the smooth muscle cells (SMC) themselves release cell derived growth factors with subsequent proliferation and migration of medial SMC through the internal elastic lamina to the area of the vessel
5 intima. Further proliferation and hyperplasia of intimal SMC and, most significantly, production of large amounts of extracellular matrix over a period of 3-6 months results in the filling in and narrowing of the vascular space sufficient to significantly obstruct coronary blood flow.

Several recent experimental approaches to preventing SMC
10 proliferation have shown promise although the mechanisms for most agents employed are still unclear. Heparin is the best known and characterised agent causing inhibition of SMC proliferation both in vitro and in animal models of balloon angioplasty-mediated injury. The mechanism of SMC inhibition with heparin is still not known but may be
15 due to any or all of the following: 1) reduced expression of the growth regulatory protooncogenes c-fos and c-myc, 2) reduced cellular production of tissue plasminogen activator, or 3) binding and dequstration of growth regulatory factors such as fibrovalent growth factor (FGF).

20 Other agents which have demonstrated the ability to reduce myointimal thickening in animal models of balloon vascular injury are angiopeptin (a somatostatin analog), calcium channel blockers, angiotensin converting enzyme inhibitors (captopril, cilazapril), cyclosporin A, trapidil (an antianginal, antiplatelet agent), terbinafine
25 (antifungal), colchicine and taxol (antitubulin antiproliferatives), and c-myc and c-myb antisense oligonucleotides.

Additionally, a goat antibody to the SMC mitogen platelet derived growth factor (PDGF) has been shown to be effective in reducing myointimal thickening in a rat model of balloon angioplasty injury, thereby
30 implicating PDGF directly in the etiology of restenosis. Thus, while no

therapy has as yet proven successful clinically in preventing restenosis after angioplasty, the in vivo experimental success of several agents known to inhibit SMC growth suggests that these agents as a class have the capacity to prevent clinical restenosis and deserve careful evaluation in humans.

Coronary heart disease is the major cause of death in men over the age of 40 and in women over the age of fifty in the western world.

Most coronary artery-related deaths are due to atherosclerosis. Atherosclerotic lesions which limit or obstruct coronary blood flow are the major cause of ischemic heart disease related mortality and result in 500,000-600,000 deaths in the United States annually. To arrest the disease process and prevent the more advanced disease states in which the cardiac muscle itself is compromised, direct intervention has been employed via percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG).

PTCA is a procedure in which a small balloon-tipped catheter is passed down a narrowed coronary artery and then expanded to re-open the artery. It is currently performed in approximately 250,000-300,000 patients each year. The major advantage of this therapy is that patients in which the procedure is successful need not undergo the more invasive surgical procedure of coronary artery bypass graft. A major difficulty with PTCA is the problem of post-angioplasty closure of the vessel, both immediately after PTCA (acute reocclusion) and in the long term (restenosis).

The mechanism of acute reocclusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a

fibrin/red blood cell thrombus. Recently, intravascular stents have been examined as a means of preventing acute reclosure after PTCA.

Restenosis (chronic reclosure) after angioplasty is a more gradual process than acute reocclusion: 30% of patients with subtotal lesions and 50% of patients with chronic total lesions will go on to restenosis after angioplasty. While the exact mechanism for restenosis is still under active investigation, the general aspects of the restenosis process have been identified:

In the normal arterial wall, smooth muscle cells (SMC) proliferate at a low rate ($<0.1\%/day$). SMC in vessel wall exists in a 'contractile' phenotype characterised by 80-90% of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, golgi bodies, and free ribosomes are few and located in the perinuclear region. Extracellular matrix surrounds SMC and is rich in heparin-like glycosylaminoglycans which are believed to be responsible for maintaining SMC in the contractile phenotypic state.

Upon pressure expansion of an intracoronary balloon catheter during angioplasty, smooth muscle cells within the arterial wall become injured. Cell derived growth factors such as platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), etc. are released from platelets (i.e., PDGF) adhering to the damaged arterial luminal surface, invading macrophages and/or leukocytes, or directly from SMC (i.e., BFGF) provoke a proliferation and migratory response in medial SMC. These cells undergo a phenotypic change from the contractile phenotype to a 'synthetic' phenotype characterised by only few contractile filament bundles but extensive rough endoplasmic reticulum, golgi and free ribosomes. Proliferation/migration usually begins within 1-2 days post-injury and peaks at 2 days in the media, rapidly declining thereafter (Campbell et al., In: Vascular Smooth Muscle Cells in Culture, Campbell, J.H. and

Campbell, G.R., Eds, CRC Press, Boca Ration, 1987, pp. 39-55) ;
Clowes, A.W. and Schwartz,. S.M., Circ. Res. 56:139-145, 1985).

Finally, daughter synthetic cells migrate to the intimal layer
of arterial smooth muscle and continue to proliferate. Proliferation and
migration continues until the damaged luminal endothelial layer
regenerates at which time proliferation ceases within the intima, usually
within 7-14 days post-injury. The remaining increase in intimal thickening
which occurs over the next 3-6 months is due to an increase in
extracellular matrix rather than cell number. Thus, SMC migration and
proliferation is an acute response to vessel injury while intimal
hyperplasia is a more chronic response. (Liu et al., Circulation, 79:1374-
1387, 1989).

Patients with symptomatic reocclusion require either repeat
PTCA or CABG. Because 30-50% of patients undergoing PTCA will
experience restenosis, restenosis has clearly limited the success of
PTCA as a therapeutic approach to coronary artery disease. Because
SMC proliferation and migration are intimately involved with the
pathophysiological response to arterial injury, prevention of SMC
proliferation and migration represents a target for pharmacological
intervention in the prevention of restenosis.

Novel Features and Applications to Stent Technology

Currently, attempts to improve the clinical performance of
endoluminal prothesis such as coronary stents have involved some
variation of either searching for a more biocompatible metal alloy,
optimising the stent surface, applying a coating to the metal, attaching a
covering or membrane, or embedding material on the surface via ion
bombardment. A stent designed to include reservoirs that can be filled up
with therapeutic agents, influencing the restenosis process has also been
proposed.

Local Drug Delivery from an endoluminal prosthesis such as a Stent to Inhibit Restenosis

5 In this application, a therapeutic agent is delivered to the site of arterial injury. The conventional approach has been to incorporate the therapeutic agent into a polymer material which is then coated on the stent. The ideal coating material must be able to adhere strongly to the metal stent both before and after expansion, be capable of retaining the drug at a sufficient load level to obtain the required dose, be able to
10 release the drug in a controlled way over a period of several weeks, and be as thin as possible so as to minimize the increase in profile. In addition, the coating material should not contribute to any adverse response by the body and should be perfectly biocompatible (i.e., should be non-thrombogenic, non-inflammatory, etc.). To date, the ideal coating
15 material has not been developed for this application.

An alternative to this polymer/drug loading method is direct binding of the therapeutic agent to the metal surface. This method has the advantage to be perfectly biocompatible. Disadvantages are however the limited dose of drug that can be loaded on the stent and the (too) fast
20 release of the drug.

An other alternative is to use a drug impregnated biocompatible glue, in particular a biocompatible oil/solvent emulsion. Also with this method the drug release is quite fast, but combination a with barrier coating could improve the release characteristics.

25 Another approach is to design a stent that contains reservoirs which could be loaded with the drug. A coating or membrane of biocompatible material could be applied over the reservoirs which would control the diffusion of the drug from the reservoirs to the arterial wall. The advantages of this system is that much more drug can be
30 loaded and much longer drug release can be achieved.

Pharmacologic attempts to prevent restenosis

Pharmacological attempts to prevent restenosis by pharmacologic means have thus far been unsuccessful and all involve systemic administration of the trial agents. Neither aspirin-dipyridamole, ticlopidine, acute heparin administration, chronic warfarin (6 months) nor methylprednisolone have been effective in preventing restenosis although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty. The calcium antagonists have also been unsuccessful in preventing restenosis, although they are still under study. Other agents currently under study include thromboxane inhibitors, prostacyclin mimetics, platelet membrane receptor blockers, thrombin inhibitors and angiotensin converting enzyme inhibitors. These agents must be given systemically, however, and attainment of a therapeutically effective dose may not be possible; antiproliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Lang et al., 42 Ann. Rev. Med., 127-132 (1991); Popma et al., 84 Circulation, 1426-1436 (1991)).

Additional clinical trials in which the effectiveness for preventing restenosis of dietary fish oil supplements, thromboxane receptor antagonists, cholesterol lowering agents, and serotonin antagonists has been examined have shown either conflicting or negative results so that no pharmacological agents are as yet clinically available to prevent post-angioplasty restenosis (Franklin, S.M. and Faxon, D.P., 4 Coronary Artery Disease, 232-242 (1993); Serruys, P.W. et al., 88 Circulation, (part 1) 1588-1601, (1993).

Stents have proven useful in reducing restenosis. Stents, which when expanded within the lumen of an angioplastied coronary artery, provide structural support to the arterial wall, are helpful in

maintaining an open path for blood flow. In two randomized clinical trials, stents were shown to increase angiographic success after PTCA, increased the stenosed blood vessel lumen and reduced the lesion recurrence at 6 months (Serruys et al., 331 New Eng Jour. Med, 495, (1994); Fischman et al., 331 New Eng Jour. Med, 496-501 (1994).
5 Additionally, in a preliminary trial, heparin coated stents appear to possess the same benefit of reduction in stenosis diameter at follow-up as was observed with non-heparin coated stents. Additionally, heparin coating appears to have the added benefit of producing a reduction in
10 sub-acute thrombosis after stent implantation (Serruys et al., 93 Circulation, 412-422, (1996). Thus, 1) sustained mechanical expansion of a stenosed coronary artery has been shown to provide some measure of restenosis prevention, and 2) coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering
15 drugs to local, injured tissue off the surface of the stent.

Numerous agents are being actively studied as antiproliferative agents for use in restenosis and have shown some activity in experimental animal models. These include: heparin and heparin fragments (Clowes and Karnovsky, 265 Nature, 25-626, (1977);
20 Guyton, J.R. et al. 46 Circ. Res., 625-634, (1980); Clowes, A.W. and Clowes, M.M., 52 Lab. Invest., 611-616, (1985); Clowes, A.W. and Clowes, M.M., 58 Circ. Res., 839-845 (1986); Majesky et al., 61 Circ Res., 296-300, (1987); Snow et al., 137 Am. J. Pathol., 313-330 (1990); Okada, T. et al., 25 Neurosurgery, 92-898, (1989), colchicine (Currier,
25 J.W. et al., 80 Circulation, 11-66, (1989), taxol, angiotensin converting enzyme (ACE)inhibitors (Powell, J.S. et al., 245 Science, 186-188 (1989), angiopeptin (Lundergan, C.F. et al., 17 Am. J. Cardiol. (Suppl. B); 132B-136B (1991), Cyclosporin A (Jonasson, L. et. al., 85 Proc. Nati, Acad. Sci., 2303 (1988), goat-anti-rabbit PDGF antibody (Ferns, G.A.A.,
30 et al., 253 Science, 1129-1132 (1991), terbinafine (Nemecek, G.M. et

al., 248 J. Pharmacol. Exp. Thera., 1167-11747 (1989), trapidil (Liu, M.W. et al., 81 Circulation, 1089-1093 (1990), interferon-gamma (Hansson, G.K. and Holm, 84 J. Circulation, 1266-1272 (1991), steroids (Colburn, M.D. et al., 15 J. Vasc. Surg., 510-518 (1992), see
5 also Berk, B.C. et al., 17 J. Am. Coll. Cardiol., 111B-1 17B (1991), ionizing radiation, fusion toxins, antisense oligonucleotides, gene vectors, and rapamycin. The systematic administration of probucol for the inhibition of atherogenesis following balloon angioplasty has been demonstrated (Schneider et al. (1993) Circulation 88: 628-637, and
10 Tardiff et al. (1996) abstract 0524, Circulation 94:1-91). The use of antioxidants and/or free-radical scavengers for inhibiting restenosis is described in U.S. 5,326,757; WO 95/26193; and CA 2106695.

WO 98/30255 teaches us the use of antioxidant substances such as probucol for inhibition of restenosis in recanalized blood vessels
15 using a special designed local drug delivery catheter.

Rapamycin coated on a stent, using a mixture of rapamycin in a polymer solution has been described in EP-A-0 950 386. Clinical studies have also shown a dramatic decrease of the restenosis rates using a rapamycin coated stent. Potential disadvantages of this system is
20 the use of rapamycin, which is a toxic drug that affects not only SMC proliferation, but also endothelial cell regrowth and restoration and fibroblast proliferation after stent implantation, and the use of a polymer which always leads to the concern of an inflammatory reaction induced by the polymer, and potentially occurrence of late restenosis.

Summary of the Invention

Melatonin (N-acetyl-5-methoxytryptamine) coated on an endoluminal prosthesis to modulate the healing response after vascular injury by decreasing vascular injury and inflammation caused by the implantation
30 of the prosthesis and resulting in a decreased neointimal hyperplasia

In accordance with the present invention, use is made of Melatonin to coat the endoluminal prothesis. In vitro evidence demonstrates that melatonin has a mode of action which is different from that of rapamycin. Melatonin has been shown to possess anti-inflammatory effects, among a number of other actions. Melatonin reduces tissue destruction during inflammatory reactions by a number of means. Melatonin, by virtue of its ability to directly scavenge toxic free radicals, reduces macromolecular damage in all organs. The free radicals and reactive oxygen and nitrogen species known to be scavaged by melatonin include highly toxic hydroxyl radicals ($\cdot\text{OH}$), peroxynitrite anion (ONOO^-), and hypochlorous acid (HOCl), among others. These agents all contribute to the inflammatory response and associated tissue destruction. Additionally, melatonin has other means to lower the damage resulting from inflammation. Melatonin prevents the translocation of nuclear factor-kappa B (NF-kappaB) to the nucleus and its binding to DNA, thereby reducing the upregulation of a variety of proinflammatory cytokines, for example, interleukins and tumor necrosis factor alpha. Finally, there is indirect evidence that melatonin inhibits the production of adhesion molecules that promote the sticking of leukocytes to endothelial cells. By this means melatonin attenuates transendothelial cell migration and edema, which contribute to tissue damage.

Although most free radical scavengers and anti-inflammatory agents are considered not potent enough to block in-stent neointimal hyperplasia sufficiently, we found a significant inhibition of peri-strut injury, peri-strut inflammation and neointimal hyperplasia in a pig stent coronary model. We found an inhibition of the same magnitude as for potent antiproliferative drugs like sirolimus and paclitaxel using the same coating technology and using the same animal model suggesting that melatonin is equipotent compared to these potent antiproliferative drugs and is more potent than pure antioxidants like probucol.

Antiproliferative drugs however are affecting all cells involved in the healing process, resulting in severe side effects. By blocking endothelial cell regrowth for example they will delay the recovery of the endothelial cells layer, resulting in a longer contact between the injured vascular wall with the circulating blood. This results in platelet activation, thrombus formation and the risk for stent thrombosis and furthermore platelets and trombine are potent activators of smooth muscle cells resulting in a continuous stimulus for neointimal hyperplasia. The inhibitory effect on fibroblast is less well understood, however could be responsible for the frequent stent malappositioning found with rapamycin coated stents. The advantage of using melatonin compared to sirolimus and especially paclitaxel is that melatonin does not block cells that are involved in the healing response. It only neutralise toxic compounds that lead to further cell damage, inflammation and an overstimulation of the smooth muscle cells resulting in neointimal hyperplasia and restenosis. Melatonin neutralises toxic compounds released by inflammatory cells in response to vascular injury. These compounds are thought to be responsible for an overstimulation of the healing response, leading to an abundant neointimal proliferation and restenosis. Melatonin has also no direct effect on the endothelial cell regrowth and indirectly, by eliminating toxic substances that also are toxic for endothelial cells, a positive effect on endothelial cell regrowth. Therefore there is no problem with potential late thrombotic occlusion of the stent by thrombus formation. Another advantage compared to the use of antiproliferative medications is that melatonin is not cytotoxic for smooth muscle cells and other cells involved in the neointimal hyperplasia cascade, even at very high drug concentrations. Therefore, by using melatonin, toxic products that increase tissue damage and by doing so overstimulate the healing response resulting in an inappropriate smooth muscle cell proliferation, neointimal hyperplasia and finally resulting in stent narrowing are

neutralised so that the stimulus for smooth muscle cell dedifferentiation and proliferation is eliminated before the neointimal hyperplasia cascade is stimulated. Different from other antioxidant drugs, melatonin has shown to have also direct effects on the inflammatory cells, inhibiting their activation during inflammatory processes after tissue injury. The importance of this pathway is not well understood, but seems to be crucial in the beneficial effects of local melatonin delivery on the healing response after vascular injury. Apart from these effects, our experimental results suggest also a direct inhibitory effect of melatonin on smooth muscle cell dedifferentiation and proliferation.

So far local delivery of melatonin was used in coated veterinary implants for regulation of seasonal breeding and other physiological responses. WO 98/30255 mentioned localized intravascular delivery of antioxidant substances, such as probucol, using a special designed local drug delivery catheter for inhibition of restenosis in recanalized blood vessels. They claim also the use of melatonin without providing any proof of concept. Disadvantage of the use of a local drug delivery balloon is that the drug can only be released during a limited time period (up to 360 seconds) and that the efficacy of effective local drug delivery to the vascular wall is very low (<1%-5%) and very variable. So far no beneficial effect of using localized intravascular delivery of antioxidant substances like described in WO 98/30255 for the inhibition of restenosis in recanalized blood vessels, using a local drug delivery balloon nor a drug coated stent has been shown.

The present invention is based on the unexpected potent beneficial effect of local, stent mediated melatonin delivery on the vascular injury and inflammation, most probably due to the potent neutralizing effect of toxic free radicals, released during injury induced inflammation, by melatonin, combined with its direct anti-inflammatory effects, resulting in an improved healing, less smooth muscle cell

stimulation and proliferation and less cellular ingrowth and narrowing of an endoluminal implant, endovascular prosthesis, shunt or catheter.

Experimental work with melatonin (N-acetyl-5-methoxytryptamine) coated coronary stents:

To get rid of the polymer, which remains always a concern when coating a drug on an endoluminal prosthesis, since several polymers have shown to be non biocompatible and to induce an inflammatory response leading to SMC proliferation and restenosis, we tried to coat melatonin directly to the surface of the endoluminal prosthesis. As endoluminal prosthesis we used a commercially available 316L stainless steel coronary stent (V-Flex Plus, 16mm/3.0mm, William Cook Europe) and the stent was dipped in a 20mg/ml ethanol solution for 30 seconds. After removal the stent was air-dried using a warm laminar flow to evaporate the ethanol. Using this method a total melatonin load on the stent of 20 µg could be achieved. Implantation of these stents in a porcine coronary model with follow-up after 5 days revealed perfect biocompatibility of the system, without inducing any inflammation surrounding the struts of the stents on histological examination. After 4 weeks a 26% decrease in neointimal hyperplasia was surprisingly found compared to a bare stent. Similar experiments, using probucol, did not result in a significant effect on inflammatory response and neointimal hyperplasia. Notwithstanding the low total dose of melatonin (20µg), significant efficacy with this system could be demonstrated. This could be explained by the 1) the potent free radical scavenging effect of melatonin, 2) the potent anti-inflammatory effect of melatonin, 3) maybe a direct effect on SMC proliferation, 4) the non toxic effect of melatonin on other mediators of the healing response.

In a next step we tried to increase the total load of melatonin by using more concentrated melatonin/ethanol solutions. By

doing so a maximum total load of 300 µg/ stent could be achieved. Porcine experiments revealed an efficient blocking of inflammatory response and neointimal hyperplasia using this high dose melatonin loaded stents.

5 A disadvantage of the direct coating system is the fast release of the drug from the stent. In-vitro release curves showed a 90% release within 24 hours. In-vivo studies however showed sufficient melatonin coronary vascular concentration up to 15 days.

10 In order to maintain significant melatonin concentrations for a longer period of time to obtain a durable anti-restenosis effect the present inventor has developed new methods to achieve a slower melatonin release. The drug was dissolved in a biocompatible emulsion of oil and a solvent wherein the drug is highly soluble. The stent was
15 dipped in this emulsion several times and in between the different dipping steps air-dried using a warm laminar flow to evaporate the solvent and harden the drug/oil coating. This system resulted in a total melatonin load per stent of 500 µg and a much slower melatonin release over a time period of weeks instead of days.

20 In-vivo work in a porcine coronary model demonstrated the perfect biocompatibility of this coating method, since no inflammation was evoked at 5 days follow-up using non drug loaded stents.

25 Sustained inhibition of peri-strut inflammation and neointimal hyperplasia was seen up to 3 months using stents loaded with 500µg of melatonin using this method. Using the same coating method, no effect of probucol was found.

Indications

30 Local delivery of melatonin by coating melatonin onto an endoluminal prosthesis, shunt or catheter and local delivery of melatonin to the surrounding tissue after implantation of the prosthesis, shunt or

catheter, resulting in an inhibition of tissue injury, inflammation and cell proliferation to prevent neointimal hyperplasia and restenosis, prevention of tumor expansion and ingrowth into an endoluminal prothesis and prevention of ingrowth of tissue into catheters and shunts inducing their failure.

Different potential delivery methods for melatonin (N-acetyl-5-methoxytryptamine):

Local delivery of melatonin, analogs or therapeutic substances with similar working mechanisms from an endovascular prothesis, catheter or shunt, from the struts of a stent, from perforations in the struts of the stents, from channels in the strut of the stent, from a hollow wire forming the stent, from a stent graft, grafts, stent cover or sheath.

Involving direct binding of the drug to the stent strut metal backbone and to the perforations, channels in the struts;

or involving a co-mixture with polymers (both degradable and nondegrading) or a biocompatible glue (in particular an oil or fat) to hold the drug to the stent or graft;

or entrapping the drug into the metal of the stent or graft body which has been modified to contain micropores, channels or perforations;

or including covalent binding of the drug to the stent via solution chemistry techniques or dry chemistry techniques (e.g. vapour deposition methods such as rf-plasma polymerization) and combinations thereof.

Extravascular delivery by the pericardial route.

Extravascular delivery by the advential application of sustained release formulations.

1. Direct drug coating on the metallic surface:

Stents are dipped in a solution of melatonin in a solvent, for example ethanol, at final concentration range 0.001 to 50 weight %. Solvent is allowed to evaporate to leave a film of melatonin on the stent.

5

2. Delivery from Polymer Matrix:

Solution of Melatonin, prepared in a solvent miscible with polymer carrier solution, is mixed with solution of polymer at final concentration range 0.001 weight % to 50 weight % of drug. Polymers are biocompatible (i.e., not elicit any negative tissue reaction or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolacton-glycolide, polyorthoesters, polyanhydrides; poly-aminoacids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof. Nonabsorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly(ethylene-vinylacetate); acrylate based polymers or copolymers, e.g., poly(hydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.

10

15

20

Polymer/drug mixture is applied to the surfaces of the stent by either dip-coating, or spray coating, or brush coating or dip/spin coating or combinations thereof, and the solvent allowed to evaporate to leave a film with entrapped Melatonin.

25

3. Delivery from a biocompatible glue (oil/solvent emulsion).

Solution of Melatonin, mixed in an oil/solvent emulsion at final concentration range 0.001 weight % to 50 weight % of drug. Emulsion/drug mixture is applied to the surface of the stent by either dip coating, or spray coating, or brush coating or dip/ spin coating or

combinations thereof, and the solvent is allowed to evaporate to leave a film of oil or fat with entrapped Melatonin.

5 4. Delivery from microporous depots, pores or perforations in stent backbone through either a Polymer Membrane Coating or Glue/drug coating:

10 A stent, whose body has been modified to contain micropores, pores, channels or perforations is dipped into a solution of Melatonin, range 0.001 wt% to saturated, in organic solvent such as acetone or methylene chloride, for sufficient time to allow solution to permeate into the pores. (The dipping solution can also be pressurised to improve the loading efficiency.) After the solvent has been allowed to evaporate, the stent is dipped briefly in fresh solvent to remove excess surface bound drug. Additionally a solution of polymer, chosen from any identified in the first experimental method, can be applied to the stent as detailed above. This outer layer of polymer will then act as release and diffusion-controller for release of drug.

15 5. Delivery via lysis of a Covalent Drug Tether

20 Melatonin is modified to contain a hydrolytically or enzymatically labile covalent bond for attaching to the surface of the stent which itself has been chemically derivatized to allow covalent immobilization. Covalent bonds such as ester, amides or anhydrides may be suitable for this.

25 6. Pericardial Delivery

30 A: Polymeric Sheet: melatonin is combined at concentration range previously highlighted, with a degradable polymer such as poly(caprolactone-glycolide) or non-degradable polymer, e.g., polydimethylsiloxane, and mixture cast as a thin sheet, thickness range

10p to 10 μ m. The resulting sheet can be wrapped perivascularly on the target vessel. Preference would be for the absorbable polymer.

5 B: Conformal coating: Melatonin is combined with a polymer that has a melting temperature higher than 37°C, more particularly in the range of 40 to 45°C. Mixture is applied in a molten state to the external side of the target vessel. Upon cooling to body temperature the mixture solidifies conformally to the vessel wall. Both non-degradable and absorbable biocompatible polymers are suitable.

10 These and other concepts are disclosed herein. It would be apparent to the reader that modifications are possible to the stent or the drug dosage applied. In any event, however, any obvious modifications should be perceived to fall within the scope of the invention which is to be realized from the attached claims and their equivalents.

CLAIMS

1. A method for modifying healing response after tissue injury caused by the implantation or insertion of an endoluminal prosthesis, catheter or shunt by the inhibition of the inflammation induced by the injury and the prevention of cell proliferation and cell ingrowth into an endoluminal prosthesis or catheter or in a shunt, using melatonin (N-acetyl-5-methoxytryptamine) or an analogue drug, applied locally as a single bioactive component or in combination with other bioactive components, by coating melatonin or the analogue drug on the prosthesis, catheter or shunt.

2. Use of melatonin (N-acetyl-5-methoxytryptamine) or an analogue drug as a single bioactive component or in combination with other bioactive components, to manufacture a pharmaceutical composition for modifying the healing response after tissue injury caused by the implantation or insertion of the endoluminal prosthesis, catheter or shunt, by the inhibition of the inflammation induced by the injury and by preventing cell proliferation and cell ingrowth into an endoluminal prosthesis or catheter or in a shunt by applying the melatonin or the analogue drug on and/or in the prosthesis, catheter or shunt.

3. An endoluminal prosthesis, shunt or catheter coated with melatonin or an analogue drug, eventually in combination with other bioactive substances, to modify the healing response after tissue injury by the inhibition of the inflammation induced by the injury, to prevent cell proliferation and cell ingrowth into the endoluminal prosthesis, shunt or catheter.

4. A melatonin (N-acetyl-5-methoxytryptamine) coated endoluminal prosthesis according to claims 1-3 wherein said prosthesis is an endovascular stent, more preferably a coronary stent.

5. A melatonin (N-acetyl-5-methoxytryptamine) coated stent according to claim 4, wherein the stent is made of a wire, optionally a

hollow wire filled with melatonin (N-acetyl-5-methoxytryptamine) or a melatonin (N-acetyl-5-methoxytryptamine) comprising product.

5 6. A melatonin (N-acetyl-5-methoxytryptamine) coated stent according to claim 4, wherein the stent comprises a generally thin walled cylinder, said cylinder containing a plurality of struts, said struts expandable depending on the amount of force applied to said strut, and said struts having a generally uniform thickness.

10 7. A melatonin (N-acetyl-5-methoxytryptamine) coated stent according to claim 4, wherein the stent comprises a generally thin walled structure containing a plurality of struts, the struts expandable to assume the shape of a lumen into which the stent is placed, said struts having a thickness and are in particular provided with one or more perforations formed in at least one of said struts, said perforations having a closed perimeter on all sides and an open top and eventually an open bottom,
15 and said perforation smaller in all dimensions than said strut, said perforation containing melatonin (N-acetyl-5-methoxytryptamine) or a melatonin comprising product applied therein.

20 8. A melatonin (N-acetyl-5-methoxytryptamine) coated stent according to claim 4, having melatonin (N-acetyl-5-methoxytryptamine) coated on the stent by either direct coating on the stent surface, by impregnating the melatonin (N-acetyl-5-methoxytryptamine) in a biocompatible oil emulsion, coated on the stent struts, or by embedding the melatonin (N-acetyl-5-methoxytryptamine) in a biocompatible polymer, coated on the stent struts, or by conjugating the
25 melatonin to any coating substance, coated on the stent struts.

9. A melatonin (N-acetyl-5-methoxytryptamine) coated stent according to claim 4, having one or more perforations, filled with melatonin (N-acetyl-5-methoxytryptamine) or a melatonin (N-acetyl-5-methoxytryptamine) containing product, either by direct coating,
30 impregnation of the melatonin (N-acetyl-5-methoxytryptamine) in a

biocompatible oil or fat emulsion, filling the perforations, impregnation of the melatonin (N-acetyl-5-methoxytryptamine) in a biocompatible polymer, filling the perforations, or conjugating the melatonin with the biocompatible oil or fat emulsion, polymer or coating substance, filling the perforations.

10. A melatonin (N-acetyl-5-methoxytryptamine) coated prosthesis, catheter or shunt according to claims 1- 3, having a total load of melatonin (N-acetyl-5-methoxytryptamine) within a range of $0.001 \mu\text{g}/\text{mm}^2$ and $50 \mu\text{g}/\text{mm}^2$, more preferably $0.1 \mu\text{g}/\text{mm}^2$ to $10 \mu\text{g}/\text{mm}^2$, and most preferably $3 \mu\text{g}/\text{mm}^2$ to $6 \mu\text{g}/\text{mm}^2$.

11. A melatonin (N-acetyl-5-methoxytryptamine) coated prosthesis, catheter or shunt according to claims 1-3, wherein the total amount of melatonin or an analogue drug is delivered over a period in the range of 360 minutes to 5 years.

ABSTRACT

"Use of Melatonin for improving the healing response after vascular injury by inhibition of inflammation induced by the injury and the prevention of cell proliferation and cell ingrowth into an endoluminal implant "

5 Delivery of Melatonin (N-acetyl-5-methoxytryptamine) locally, particularly from an intraluminal prothesis such as a coronary stent, directly from the surface of the prothesis or from pores, micropores, or perforations in the stent body, mixed or bound to a polymer coating applied on the endoluminal prothesis, or mixed or bound to a glue applied to the endoluminal prothesis, to inhibit inflammation induced by the injury caused by the implantation of the prothesis and neointimal tissue proliferation and ingrowth of tissue, thereby facilitating the performance of the prothesis.

PCT/EP2004/051755

